THE IMMUNE RESPONSE CORPORATION PRESENTS UPDATED INTERIM NEUROVAX DATA
The Immune Response Corporation has announced that its NeuroVax restored normal
levels of FOXP3 and regulatory T-cells, as well as increased IL-10 secretion
in multiple sclerosis (MS) patients, in an ongoing Phase I/II clinical study.
FOXP3, T-reg cells and IL-10 are known to play important roles in regulating
the immune system. The data was presented at the
21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Greece.
In clinical research, NeuroVax demonstrated strong immune responses, as measured by limiting dilution assay, in a subgroup of six MS patients analyzed after 48 weeks of monthly injections. As a group, they had increased their FOXP3 regulatory T-cells to levels equal to those seen in healthy controls. Data were also presented from a previous blinded, controlled trial showing that 12 patients with positive MRI lesions at baseline all responded immunologically to NeuroVax.